Environmental Effects of Illicit Drug Production

Fosun Receives RMB12 Billion Syndicated Loan to Consolidate Capital for Business Development

Retrieved on: 
Tuesday, January 17, 2023
The Bund Finance Center, Bank of China, News, Fosun Pharma, PE, COFCO, Attention, Bank, Agricultural Bank, Club Med, China International Capital Corporation, CICC, Industrial and Commercial Bank of China, COVID-19, Statistics, HKEX, Commercial bank, Health, Pfizer–BioNTech COVID-19 vaccine, Communication, Security, China Minsheng Bank, Exim Bank, Iron, Happiness, NAV, Central Economic Work Conference, Conference, Environmental Effects of Illicit Drug Production, Policy, Tsingtao Brewery, Omicron, China Construction Bank, Research, New Year, Bank of Communications, Shanghai Pudong Development Bank, Nanjing Iron and Steel Company, Research report, Agricultural Bank of China, Optimism, Security (finance), Risk management, Fosun International, Azvudine

According to the Company's official release, Guo Guangchang, Chairman of Fosun International said that this signing has further deepened the cooperation between Fosun and banks, broadened financing channels, and consolidated liquidity support for business development.

Key Points: 
  • According to the Company's official release, Guo Guangchang, Chairman of Fosun International said that this signing has further deepened the cooperation between Fosun and banks, broadened financing channels, and consolidated liquidity support for business development.
  • Before the RMB12 billion syndicated loan was officially completed, on 13 January, Fosun High Technology successfully completed bookbuilding for the RMB1 billion super & short-term commercial paper "23 Fosun High Technology SCP001" with a term of 180 days and a coupon rate of 6.99% per annum.
  • The super & short-term commercial paper is Fosun High Technology's first issuance since its return to the public market at the end of April 2022.
  • In addition to this syndicated loan and the super & short-term commercial paper, Fosun's capital has been further consolidated.

Herborium®’ Group Half Year Update

Retrieved on: 
Thursday, July 21, 2022
AI, GLOBE, United Kingdom, OTC Markets Group, Environmental Effects of Illicit Drug Production, Woman, Compliance, Private Securities Litigation Reform Act, Safety, Annual awards of Chinese highest tier football league, Manifest and latent functions and dysfunctions, Beauty, Consortium, Acne, Company, Topical steroid withdrawal, Man, Safe harbor (commerce), Growth, OTC, Security (finance), Industry

Herborium Group, Inc. (OTC Pink: HBRM ), a Botanical Therapeutics Company and provider of unique, all botanical medicinal, beauty and wellness products with a clinically validated records of efficacy and safety, announced today the following accomplishments for the first half of 2022.

Key Points: 
  • Herborium Group, Inc. (OTC Pink: HBRM ), a Botanical Therapeutics Company and provider of unique, all botanical medicinal, beauty and wellness products with a clinically validated records of efficacy and safety, announced today the following accomplishments for the first half of 2022.
  • Herborium Group, Inc., a botanical therapeutics company that develops, license and markets proprietary, botanical based medicinal and wellness products to consumers and healthcare professionals.
  • Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
  • For more information, please visit www.herborium.com , www.acnease.com , www.acnease.fr and www.acneasesp.com
    Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties.

Herborium® Enters $220Billion Digital Content Market

Retrieved on: 
Tuesday, May 10, 2022
United Kingdom, Private Securities Litigation Reform Act, COVID-19, Woman, GLOBE, Company, Health, Safety, Consortium, Environmental Effects of Illicit Drug Production, Model, Diagnosis, Industrial Internet Consortium, OTC Markets Group, Platform, Artificial intelligence, Beauty, Commerce, Topical steroid withdrawal, International Safe Harbor Privacy Principles, Technology, Growth, Manifest and latent functions and dysfunctions, Man, Dietary supplement, Pharmaceutical industry, Retail, Video game, Industry, AI

Herborium Self-Care platform is to integrate not only Herborium products, expertise, and content but also those of qualified partners to provide the most comprehensive, multi-facet hosting and delivery digital tool in natural selfcare and beauty.

Key Points: 
  • Herborium Self-Care platform is to integrate not only Herborium products, expertise, and content but also those of qualified partners to provide the most comprehensive, multi-facet hosting and delivery digital tool in natural selfcare and beauty.
  • Herborium Group, Inc., a botanical therapeutics company that develops, license and markets proprietary, botanical based medicinal and wellness products to consumers and healthcare professionals.
  • The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk,ethical pharmaceuticals and commoditized classic nutraceuticals (supplements).
  • Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

Herborium® Surpasses Million Dollar Sales Mark; Reduces Outstanding Debt and Dilution

Retrieved on: 
Tuesday, May 3, 2022
United Kingdom, Private Securities Litigation Reform Act, GLOBE, Company, Environmental Effects of Illicit Drug Production, Safety, Annual report, OTC Markets Group, Beauty, Sale, Safe harbor (commerce), Growth, Manifest and latent functions and dysfunctions, Industry

In addition, the Company significantly decreased its debt by eliminating over $250,000 in Notes Debt.

Key Points: 
  • In addition, the Company significantly decreased its debt by eliminating over $250,000 in Notes Debt.
  • This prevents future dilution and is important part of Companys effort of increasing shares price.
  • Herborium expects to continue the sales increase in 2022 through the number of upcoming changes and special projects we will be announcing shortly.
  • Herborium Group, Inc., a botanical therapeutics company that develops, license and markets proprietary, botanical based medicinal and wellness products to consumers and healthcare professionals.